 | ||
   | ||
Email
Glossary |
|
baraclude Sep 16, 2007 Baraclude is carcinogenic on Rodent with low doses according to ASSLD. Is this a concern for patient who starts treatment with baraclude. Tyzeka and hepsera do not seem to have have this issue. What is the drug preference for treating precore mutant HBV (e-antigen negative)? Is Tyzeka better since its profile regaring carcinogen is better? |
||||||||
 |
||||||||||
|
||||||||||
 |
| Response from Dr. McGovern
 Telbivudine (Tyzeka) is not carcinogenic in mice at doses up to 14 times that used in humans. Adefovir is not carcinogenic in mice at doses up to 10 times that used in humans. Entecavir (Baraclude) was shown to be carcinogenic in mice - but this was at 42 times the dose that is normally given to humans! These types of studies are done all the time in the pharmaceutical industry. These data are actually reassuring. The bottom line is that all three drugs appear to be safe in the normal doses used in humans. | ||||||||
 Get Email Notifications When This Forum Updates or Subscribe With RSS
|
||||||||||
|
||||||||||
Q&A TERMS OF USE
This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.
Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.
Review our complete terms of use and copyright notice.
